Monopar Therapeutics Inc.
MNPR
$41.96
-$1.19-2.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -502.33% | 33.24% | 22.03% | 32.59% | 37.37% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 918.75% | -58.00% | -29.35% | -30.97% | 20.54% |
| Change in Net Operating Assets | 2,086.57% | 106.89% | 21.05% | -9.62% | -117.17% |
| Cash from Operations | -29.27% | 44.66% | 20.21% | 27.11% | -18.75% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -582.71% | 7,624.43% | -100.08% | 0.01% | 160.39% |
| Cash from Investing | -582.71% | 7,624.43% | -100.08% | 0.01% | 160.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16,435.39% | -100.00% | -99.98% | 288.58% | 210.98% |
| Repurchase of Common Stock | -1,162.26% | -101.22% | 39.76% | 36.31% | 72.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16,682.30% | -106.69% | -101.54% | 295.37% | 141.17% |
| Foreign Exchange rate Adjustments | 54.76% | -33.82% | 134.09% | 84.26% | 82.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,173.16% | 94.13% | -213.32% | 122.01% | 128.56% |